Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd (TEVA) is a global pharmaceutical company best known for its large generics business and select specialty medicines. With a market capitalisation near $22 billion, Teva supplies a broad range of off‑patent medicines alongside branded treatments in areas such as central nervous system disorders. The company has undergone significant restructuring in recent years to cut costs, manage debt and refocus R&D. Key investor considerations include pricing pressure in generics, patent cliffs for older products, ongoing litigation and the balance sheet after past acquisitions. At the same time, scale in manufacturing, a diversified product mix and potential upside from speciality drugs or successful pipeline assets can support recovery. Investors should weigh Teva’s income statement trends, cash generation, debt reduction progress and the regulatory environment. This is general information for educational purposes only and not personalised investment advice; stock prices can fall as well as rise.
Why It's Moving
Teva Scores Major EU Wins with New Biosimilar Approvals for Blockbuster Drugs
Teva Pharmaceutical Industries received European Commission approvals on November 25, 2025, for PONLIMSI® (biosimilar to Prolia®) and DEGEVMA® (biosimilar to Xgeva®), bolstering its biosimilars portfolio amid ongoing growth momentum. These nods signal accelerated revenue potential from high-demand osteoporosis and cancer treatments, reinforcing Teva's Pivot to Growth strategy.
- European approvals for denosumab biosimilars target Prolia® and Xgeva®, unlocking access to multibillion-dollar markets in bone health and oncology.
- Builds on Q2 2025's 10th straight quarter of growth, driven by innovative products up 26% in local currency.
- Supports biosimilars revenue doubling goal from 2024 to 2027, with two more U.S. launches eyed for late 2025.
Teva Scores Major EU Wins with New Biosimilar Approvals for Blockbuster Drugs
Teva Pharmaceutical Industries received European Commission approvals on November 25, 2025, for PONLIMSI® (biosimilar to Prolia®) and DEGEVMA® (biosimilar to Xgeva®), bolstering its biosimilars portfolio amid ongoing growth momentum. These nods signal accelerated revenue potential from high-demand osteoporosis and cancer treatments, reinforcing Teva's Pivot to Growth strategy.
- European approvals for denosumab biosimilars target Prolia® and Xgeva®, unlocking access to multibillion-dollar markets in bone health and oncology.
- Builds on Q2 2025's 10th straight quarter of growth, driven by innovative products up 26% in local currency.
- Supports biosimilars revenue doubling goal from 2024 to 2027, with two more U.S. launches eyed for late 2025.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Teva's stock with a target price of $27.88, indicating potential growth.
Financial Health
Teva is producing solid revenue and profits, supported by strong cash flow and margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TEVA
Domestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Volume & Scale
Teva’s large manufacturing footprint drives cost advantages in generics, which can support margins — though pricing pressure and competition remain important caveats.
Speciality Pipeline Focus
Selective branded assets and R&D in areas like CNS could offer upside if successful, but development outcomes and regulatory hurdles create uncertainty.
Balance Sheet Watch
Investors often focus on debt reduction and cash flow recovery; improvements can strengthen prospects, while unresolved liabilities can limit flexibility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
